Ad19a/64 Adenoviral Vector

Ad19a/64 vector for vaccination

Our proprietary Ad19a/64 vector (Subtype D) can be used to overcome the low transduction efficiency of commonly used adenovirus (Ad) serotypes and help overcome the challenge of pre-existing immunity against commonly used adenovirus serotypes. It is an attractive alternative for the most commonly used human adenovirus type 5 (Ad5) for specific types of applications.

This adenoviral vaccine vector demonstrates a higher transduction efficiency in various human cells (e.g., dendritic cells, cardiomyocytes, fibroblasts, PBMCs, myoblasts, and myotubes) compared to Ad5, as supported by preclinical data. It also possesses CAR-independent binding properties, targeting sialic acid-dependent receptors. Preclinical research vaccine studies in non-human primates, indicate that the vector may potentially enhance CD4 and CD8 immune responses.

Key benefits of our Ad19a/64 adenoviral vaccine vector

• Efficient gene transfer to human DCs and skeletal muscle cells
• Low seroprevalence within the human population
• Transduction experiments with human myoblasts and primary myotubes

Here we share some data to demonstrate how the Ad19a/64 vector transduces human myoblasts and primary myotubes.